China Cosmetics Update: 137 New Ingredients Added to IECIC — What Brands Need to Know Now

On March 21, 2024, China’s National Institutes for Food and Drug Control (NIFDC) released the latest update to the 已使用化妆品原料名称目录 (IECIC, Inventory of Existing Cosmetic Ingredients in China, yǐ shǐyòng huàzhuāngpǐn yuánliào míngchēng mùlù), adding 137 new ingredients to the approved list. This brings the total IECIC catalogue to 9,050 ingredients, up from 8,964 in the previous 2021 edition — a net increase of 0.96% over three years. The update reflects China’s accelerated push to align domestic ingredient approvals with global innovation trends, particularly in biotech, fermentation-derived actives, and sustainable preservatives.

What Changed in the 2024 IECIC Update

The 2024 IECIC revision is the first major expansion since the 2021 edition and the largest single addition of new ingredients since the cosmetics regulatory overhaul under the 化妆品监督管理条例 (Cosmetics Supervision and Administration Regulations, CSAR, huàzhuāngpǐn jiāndū guǎnlǐ tiáolì) took full effect in 2021. Of the 137 new entries, approximately 30% (41 ingredients) are from biotechnology and fermentation processes, 15% (20 ingredients) are new active ingredients for sunscreen and anti-aging claims, and the remaining 55% (76 ingredients) cover emollients, humectants, preservatives, and texture modifiers.

The 60-day public comment period closed in May 2024, and the final list was officially adopted with only minor clarifications on CAS numbering. Notably, 5 proposed ingredients were rejected during the comment phase due to insufficient safety data — underscoring the NIFDC’s continued emphasis on rigorous toxicological assessment before inclusion.

Why the IECIC Update Matters for Global Cosmetics Brands

For foreign brands planning to export or manufacture cosmetics in China, the IECIC update has direct implications for 注册备案 (registration and filing, zhùcè bèi’àn). Ingredients on the IECIC can be used in registered products without the need for a full new-ingredient safety assessment under the 化妆品新原料注册备案 (new cosmetic ingredient registration, huàzhuāngpǐn xīn yuánliào zhùcè bèi’àn) pathway. This significantly reduces the timeline and cost of bringing products to market. The 137 new additions mean that brands using these ingredients can now fast-track their NMPA (National Medical Products Administration, guójiā yàopǐn jiāndū guǎnlǐ jú) registration, cutting approval time by an estimated 6 to 12 months compared to filing as a new ingredient.

In comparison, the previous IECIC update in 2021 added only 78 new ingredients, while the 2019 inaugural CSAR-era update added 54. The 2024 figure of 137 represents a 75% increase over the 2021 addition, signaling that the NIFDC is actively clearing a backlog of ingredients that have been pending review since 2022. This is a positive signal for brands that have delayed 中国市场进入 (China market entry, zhōngguó shìchǎng jìnrù) due to ingredient restrictions. According to CG360-BEAUTY tracking data, international brands cited ingredient approval delays as the #2 barrier to China launch in our 2023 survey (behind only distribution complexity).

The update also aligns with China’s 美妆大国战略 (cosmetics powerhouse strategy, měizhuāng dàguó zhànlüè), which aims to position China as a global leader in cosmetic innovation by 2030. The inclusion of biotech-derived ingredients supports the domestic push toward 合成生物学 (synthetic biology, héchéng shēngwùxué) and 绿色制造 (green manufacturing, lǜsè zhìzào), trends that are reshaping the global cosmetics R&D landscape.

Navigating Registration and Compliance Post-Update

While the IECIC addition is welcome news, brands must navigate several procedural nuances to avoid compliance missteps. First, inclusion in the IECIC does not automatically validate all product formulations — the 已使用化妆品原料目录 (existing ingredients catalogue, yǐ shǐyòng huàzhuāngpǐn yuánliào mùlù) specifies allowable concentration levels and usage restrictions for many ingredients. Brands must cross-reference the exact CAS number and approved functions against their intended application. Second, the update introduces 12 new restricted-use ingredients that require additional safety dossiers even though they are on the IECIC — a subtle but critical distinction.

Third, the NIFDC has tightened documentation requirements for imported products using ingredients that were added in this update. Specifically, for the 20 new sunscreen/anti-aging actives, brands must submit stability and efficacy test reports conducted in CNAS-certified labs (China National Accreditation Service for Conformity Assessment, zhōngguó hé gé píngdìng guójiā rènkě wěiyuánhuì) or equivalent international bodies. The cost of stabilizing documentation for a single ingredient can range from RMB 50,000 to RMB 120,000, depending on testing complexity.

For brands operating across multiple provinces, note that 备案 (filing, bèi’àn) for non-special-use cosmetics using these new ingredients is handled at the provincial level, and processing times vary. Shanghai’s Municipal Drug Administration, for example, processes filings in 15 business days, while some inland provinces require up to 30 business days. This disparity can affect launch timelines for brands with multi-city distribution strategies.

Decision Framework for Brands Considering New IECIC Ingredients

If your product formula relies on an ingredient that was added to the IECIC in this 2024 update — and your target claim is in the sunscreen, anti-aging, or biotech category — choose to fast-track registration via the IECIC pathway, as this will save 6–12 months compared to new-ingredient filing. If your product uses an ingredient not yet on the IECIC and not covered by the update, choose to pursue a full new-ingredient registration under the CSAR framework, allowing you to secure proprietary advantages and a 3-year data protection period if approved.

3 Critical Pitfalls for Global Brands